Optimal interval for delayed retrieval surgery with reciprocating morcellators after enucleation of giant prostatic hyperplasia in holmium laser enucleation of the prostate

Objective:The aim of this research was to evaluate the efficiency of reciprocating morcellation for removing giant benign prostatic hyperplasia during holmium laser enucleation of the prostate,investigate whether performing morcellation as a two-stage procedure improves tissue retrieval efficiency,and seek to determine the optimal interval between the two surgeries.Methods:This study included nine cases of holmium laser enucleation of the prostate with an enucleated prostate weight exceeding 200 g,indicative of substantial prostate enlargement.Morcellation was performed on Day 0(n=4),Day 4(n=1),Day 6(n=1),and Day 7(n=3).The intervals were compared regarding the morcellation efficiency,beach ball presence,and pathology.Results:The mean estimated prostate volume was 383(range 330e528)mL;the median enucleation weight was 252(interquartile range[IQR]222,342)g;and the median enucleation time was 83(IQR 62,100)min.The mean morcellation efficiency was 1.44(SD 0.55)g/min on Day 0 and 13.69(SD 2.46)g/min on day 7.The morcellation efficiency was 4.15 g/min and 10.50 g/min on Day 4 and Day 6,respectively,with significantly higher in the two-stage group compared to one-stage group(11.0 g/min vs.1.5 g/min;p=0.014).Efficiency was strongly correlated with intervals(p<0.001);the incidences of beach balls were 100%(4/4)and 60%(3/5)in the immediate and two-stage surgery groups,respectively.Conclusion:The efficiency of two-stage morcellation with reciprocating morcellators was highly related to the postoperative interval,with the maximum efficiency reached on Day 7.

Primary prostate Burkitt's lymphoma resected with holmium laser enucleation of the prostate:A rare case report

BACKGROUND Primary prostate Burkitt's lymphoma is a rare and aggressive condition with a poor prognosis.Its clinical presentation can be challenging to differentiate from benign prostatic hyperplasia.Given the rarity of primary prostate Burkitt's lymphoma,its diagnosis and treatment remain unclear.CASE SUMMARY This report presents a case of a 57-year-old male with primary prostate Burkitt's lymphoma,initially misdiagnosed as prostatic hyperplasia.This case's operative process,intraoperative findings and postoperative management are discussed in detail.CONCLUSION Primary prostate lymphoma is difficult to distinguish from other prostate diseases.Holmium laser enucleation of the prostate(HoLEP),a minimally invasive procedure,is crucial in diagnosing and treating this rare disease.Clinicians should remain vigilant and thoroughly combine physical examination,imaging and test results when encountering patients of younger age with small prostate size but a rapid progression of lower urinary tract symptoms.HoLEP is an essential diagnostic and therapeutic tool in managing primary prostate Burkitt's lymphoma.

Feasibility of en bloc thulium laser enucleation of the prostate in a large case series. Are results enhanced by experience?

Objective:To provide the first large single-operator case series of patients who undergo“en bloc”thulium laser enucleation of the prostate(ThuLEP)and to demonstrate an improvement in enucleation efficacy with experience.Methods:We prospectively evaluated a cohort of patients with symptomatic benign prostatic hyperplasia(BPH)who underwent“en bloc”ThuLEP between May 2015 and November 2017.Association between dependent variables(delivered energy and operating time)and independent variables(adenoma volume and experience)were estimated with regression analysis.The experience was calculated as the time interval between the date of the first operation of the series and the date of the operation being considered.Results:A total of 100 patients were registered for the study.Median operative time was 56.5 min(interquartile range[IQR]:40-85 min).Median enucleation time was 17.4 min(IQR:15-21.5 min).Median enucleation index(enucleation time per adenoma gram)was 0.3 min/g(0.2-0.3 min/g).The overall operative time is not influenced by experience,but we registered a significant trend towards a reduction in the total amount of energy delivered energy normalized per adenoma gram(p=0.0148).Conclusion:We believe that further attention is needed for these new“en bloc”prostatic enucleation techniques,which can facilitate some surgical steps,leading to a widespread use of laser technology for BPH surgical treatment.

Transurethral prostate enucleation with 2 μm laser in treatment of benign prostatic hyperplasia

Objective To investigate the feasibility and efficacy of transurethral prostate enucleation with 2 μm laser in treatment of benign prostatic hyperplasia ( BPH) . Methods One hundred and seven patients with BPH were treated by transurethral prostate enucleation with 2 μm la-

Incidence of urinary incontinence following endoscopic laser enucleation of the prostate by en-bloc and non-en-bloc techniques:a multicenter,real-world experience of 5068 patients

We aim to evaluate the incidence of incontinence following laser endoscopic enucleation of the prostate(EEP)comparing en-bloc(Group 1)versus 2-lobe/3-lobe techniques(Group 2).We performed a retrospective review of patients undergoing EEP for benign prostaticenlargement in 12 centers between January 2020 and January 2022.Data were presented as median and interquartile range(IQR).Univariable and multivariable logistic regression analysis was performed to evaluate factors associated with stress urinary incontinence(SUI)and mixed urinary incontinence(MUI).There were 1711 patients in Group 1 and 3357 patients in Group 2.Patients in Group 2were significantly younger(68[62–73]years vs 69[63–74]years,P=0.002).Median(interquartile range)prostate volume(PV)wassimilar between the groups(70[52–92]ml in Group 1 vs 70[54–90]ml in Group 2,P=0.774).There was no difference in preoperativeInternational Prostate Symptom Score,quality of life,or maximum flow rate.Enucleation,morcellation,and total surgical time weresignificantly shorter in Group 1.Within 1 month,overall incontinence rate was 6.3%in Group 1 versus 5.3%in Group 2(P=0.12),and urge incontinence was significantly higher in Group 1(55.1%vs 37.3%in Group 2,P<0.001).After 3 months,the overall rate ofincontinence was 1.7%in Group 1 versus 2.3%in Group 2(P=0.06),and SUI was significantly higher in Group 2(55.6%vs 24.1%in Group 1,P=0.002).At multivariable analysis,PV and IPSS were factors significantly associated with higher odds of transient SUI/MUI.PV,surgical time,and no early apical release technique were factors associated with higher odds of persistent SUI/MUI.

Search trends in the treatment for benign prostatic hyperplasia:A twenty-year analysis

ObjectiveMinimally invasive treatments for benign prostatic hyperplasia (BPH) have seen an increase in usage in recent years. We aimed to determine what types of events may influence patient search habits related to surgical BPH treatments.MethodsGoogle Trends was used to determine the frequency of searches for different minimally invasive and prostatic ablative treatments for BPH in the United States. The procedures including transurethral resection of the prostate (TURP), Aquablation therapy (Aquablation), Greenlight laser therapy (Greenlight), transurethral needle ablation, transurethral microwave thermotherapy, Urolift (prostatic urethral lift [PUL]), Rezum, iTind, holmium laser enucleation of the prostate, simple prostatectomy, and prostatic artery embolization were compared.ResultsFrom January 1, 2004 to February 28, 2023, the number of internet search queries have increased for TURP, PUL, Rezum, prostatic artery embolization, and holmium laser enucleation of the prostate. There has been a slight decrease in searches for Greenlight, transurethral needle ablation, transurethral microwave thermotherapy, iTind, simple prostatectomy, and Aquablation.ConclusionDespite increased searches of alternatives, TURP remains the most searched BPH procedure. Additionally, search habits may be influenced by several factors including government approval, corporate acquisition, and marketing campaigns. It is important for physicians to understand the types of events that may cause patients to inquire about certain treatments for better quality health information and clinical visits.

Sexual outcome of patients undergoing thulium laser enucleation of the prostate for benign prostatic hyperplasia

Treatment of patients with lower urinary tract symptoms （LUTS） secondary to benign prostatic hyperplasia （BPH） may affect the quality of sexual function and ejaculation. The effect of new surgical procedures, which are currently available to treat BPH, on erection and ejaculation, has been poorly studied. This study aimed to assess the effect of thulium laser enucleation of the prostate （ThuLEP） on sexual function and retrograde ejaculation in patients with LUTS secondary to BPH. We performed a prospective study in 110 consecutive patients who had undergone ThuLEP to analyze changes in sexual function and urinary symptoms. To evaluate changes in erection and ejaculation, and the effect of urinary symptoms on the quality of life （QoL）, five validated questionnaires were used： the ICIQ-MLUTSsex, MSHQ-EjD, International Index of Erectile Function 5, International Prognostic Scoring System （IPSS） questionnaire, and QoL index of the intraclass correlation coefficients. Patients also underwent IPSS and flowmetry to assess the outcome of flow. Patients were evaluated before surgery and 3-6 months after ThuLEP, whereas those with previous abdominal surgery were excluded. The patients＇ mean age was 67.83 years. Postoperative urinary symptoms improved after surgery. No significant differences in erectile function before and after surgery were observed. As compared with other techniques described in the literature, the percentage of patients with conserved ejaculation increased by 52.7% after ThuLEP. ThuLEP positively affects urinary symptoms and their effect on the QoL of patients as assessed by questionnaire scores. While endoscopic management of BPH （e.g. transurethral resection of the prostate） causes retrograde ejaculation in most patients, those who undergo ThuLEP have conserved ejaculation and erectile function.

Management of urethral strictures and stenosis caused by the endo-urological treatment of benign prostatic hyperplasiad-a single-center experience

Objective:Urethral stricture disease after endo-urological treatment of benign prostatic hyperplasia(BPH)is a sparsely described complication.We describe management of five categories of these strictures in this retrospective observational case series.Methods:One hundred and twenty-one patients presenting with symptoms of bladder outflow obstruction after endo-urological intervention for BPH from February 2016 to March 2019 were evaluated.Among them,76 were eligible for this study and underwent reconstructive surgery.Preoperative and postoperative assessments were done with symptom scores,uroflowmetry,ultrasound for post-void residue,and urethrogram.Any intervention during follow-up was classed as a failure.The recurrence and 95%confidence interval for recurrence percentage were calculated.Results:The following five categories of patients were identified:Bulbo-membranous(33[43.4%]),navicular fossa(21[27.6%]),penile/peno-bulbar(8[10.5%]),bladder neck stenosis(6[7.9%]),and multiple locations(8[10.5%]).The average age was 69 years(range:60-84 years).Overall average symptom score,flow rate,and post-void residue changed from 21 to 7,6 mL/s to 19 mL/s,and 210 mL to 20 mL,respectively.The average follow-up was 34 months(range:12-58 months).Overall recurrence and complication rates were 10.5%and 9.2%,respectively.The recurrence in each category was seen in 3,1,2,1,and 1 patient,respectively.Overall 95% confidence interval for recurrence percentage was 4.66-19.69.Conclusion:Urethral stricture disease is a major long-term complication of endo-urological treatment of BPH.The bulbo-membranous strictures need continence preserving approach.Navicular fossa strictures require minimally invasive and cosmetic consideration.Peno-bulbar strictures require judicious use of grafts and flaps.Bladder neck stenosis in this cohort could be treated with endoscopic measures.Multiple locations need treatment based on their sites in single-stage as far as possible.

Best surgical treatment for very large benign prostatic obstruction

AIM:To investigate the best surgical treatment for very large benign prostatic obstruction(BPO).METHODS:A revision of literature was conducted in Pub Med database with 167 search results.Key words for the search were benign prostatic hyperplasia,surgical treatment,large,and volume.Inclusion criteria for this study were surgical treatment of benign prostatic obstruction for prostates equal to or larger than 80 cc.Among article search results,9 completed inclusion criterion and were revised.Each surgical technique included in those articles was compared to each other.The results were observed,and conclusions derived from this are presented.There is no statistical analysis.RESULTS:Of the 5 techniques presented in the revised articles[open transvesical enucleation,holmiumlaser enucleation of the prostate(HoL EP),photoselective vaporization of the prostate using potassium titanyl phospate laser,transurethral resection with bipolar energy,and transurethral enucleation with bipolar energy],open transvesical enucleation best permits the resolution of obstructive symptoms.It presents excellent maximum flow rates,high resected tissue volume and maintenance of results over time.These characteristics explain why it has been the gold standard treatment for prostates greater than 80 cc.However,it is at the expense of greater blood loss,urethral catheter and hospital stay times.Since its initial application in1996,the transurethral enucleation of the prostate by means of a holmium laser has become a procedure that has similar surgical outcomes with fewer complications when compared to open surgery making it an interesting alternative for very large BPO.Nonetheless,no procedure has removed open surgery as the gold standard for very large BPO.CONCLUSION:Open surgery has proved to be the gold standard for very large BPO.HoL EP appears as a minimally invasive alternative with same benefits but less morbidity.

Predictive Factors for a Successful Day Case Benign Prostatic Hyperplasia Surgery: A Review

Introduction: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) is one among the foremost common diseases affecting the aging man with, almost 80% of the lads greater than 70 affected. BPH is caused by unregulated proliferation within the prostate, which may cause physical obstruction of the prostatic urethra and result in anatomic bladder outlet obstruction (BOO). Transurethral resection of the prostate (TURP) has been the historical gold standard up till now to which all endoscopic procedures for benign prostatic hyperplasia (BPH) are compared with a mean hospital stay of three days. This surgery although efficacious has been related with increased morbidity and increased day case failure rates as compared to newer techniques. These shortcomings have prompted the utilization of newer methods like Transurethral enucleation and resection of the prostate (TUERP), Holmium laser enucleation of the prostate (HoLEP) and Thulium laser enucleation of the prostate (ThuLEP). This review will discuss the enucleation techniques, advantages and therefore the predictive factors for a successful day case prostate surgery. Materials and Methods: During this review, we discuss the newer techniques utilized in day case BPH surgery as well as the predictive factors for a successful BPH surgery, both enucleation, benefits and morcellation are covered also. Results: TUERP, ThuLEP and HoLEP have literature supporting the advantages of these techniques, which demonstrates its ability in day case BPH surgeries in specially selected cases with favorable factors and a 61% overall success rate. Conclusion: TUERP, ThuLEP and HoLEP Have proven to show favorable outcomes in day case BPH surgery with urologist’s experience, prostate size, duration of operation, age, use of anticoagulants, morning theatre list and ASA score being the key factors for a successful day case surgery.

半导体激光剜除术对前列腺增生患者尿动力学、血清睾酮、PSA水平的影响

目的探讨半导体激光剜除术对前列腺增生患者尿动力学、血清睾酮、前列腺特异抗原(PSA)水平的影响。方法前瞻性选取2021年2月至2023年2月在大庆龙南医院就诊的90例前列腺增生患者作为研究对象,按随机数字表法将其分为观察组与对照组,每组各45例。观察组行半导体激光剜除术,对照组行前列腺电切术。比较两组围手术期指标、术后并发症及手术前后的残余尿量(PVR)、最大尿流率(Qmax)、睾酮、PSA、国际前列腺症状评分(IPSS)、生活质量量表(QOL)。结果观察组的手术时间、术中出血量、术后膀胱冲洗时间、术后留置导管时间、住院时间分别为(69.88±10.26)min、(40.23±6.28)mL、(20.04±5.19)h、(2.96±0.81)d、(4.29±1.12)d,均显著少于对照组[(77.76±9.74)min、(64.11±8.75)mL、(27.83±8.34)h、(4.61±1.51)d、(6.02±1.45)d],差异均有统计学意义(P<0.05)。两组术后残余尿量均较术前显著降低,Qmax均较术前显著升高,观察组残余尿量为(9.04±2.37)mL,低于对照组[15.08±4.24)mL],Qmax为(26.97±8.02)mL/s,高于对照组[(18.55±7.23)mL/s],差异均有统计学意义(P<0.05)。两组术后血清睾酮、PSA水平均较术前显著降低,观察组血清睾酮、PSA水平分别为(18.71±1.04)mmol/L、(4.36±1.08)ng/mL,均低于对照组[(21.05±1.15)mmol/L、(8.08±1.69)ng/mL],差异均有统计学意义(P<0.05)。两组术后IPSS、QOL评分均较术前显著降低,观察组IPSS、QOL评分分别为(6.10±1.25)、(1.23±0.29)分,均低于对照组[(8.23±1.31)、(1.77±0.56)分],差异均有统计学意义(P<0.05)。观察组术后并发症总发生率为13.33%,显著低于对照组(31.11%),差异有统计学意义(P<0.05)。结论半导体激光剜除术在改善前列腺增生患者尿动力学及血清睾酮、PSA水平等方面效果优于前列腺电切术。

钬激光“ω”形预离断前列腺尖部保留膀胱颈对良性前列腺增生患者术后控尿和性功能的影响

目的:探讨钬激光“ω”形预离断前列腺尖部保留膀胱颈对良性前列腺增生患者经尿道前列腺钬激光剜除(HoLEP)术后控尿和性功能的影响。方法:回顾分析165例于2018年1月至2023年1月在延安大学附属医院接受钬激光“ω”形预离断前列腺尖部保留膀胱颈治疗良性前列腺增生患者的临床资料。记录患者基线资料、围手术期数据,随访12个月。排尿功能采用国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、残余尿(PVR)和生活质量(QOL)评分进行评估。对于所有术前有性活动并有正常顺行射精的患者,术后评估射精情况和勃起功能。结果:手术时间为(70.35±12.27)min,术中出血量为(60.12±19.54)ml,切除腺体重量为(56.37±13.71)g;住院时间和术后留置导尿管时间分别为(5.13±2.34)d和(3.21±1.37)d;与术前比较,术后3、6、12个月IPSS、QOL、PVR和Qmax等指标均有显著改善(P<0.05),且在随访过程中持续稳定。术后3个月时随访压力性尿失禁发生率为10.91%,多数患者在术后12个月内恢复,长期尿失禁1例(0.6%);对于性功能评估,术后国际勃起功能问卷评分及勃起硬度分级量表均无显著变化(P>0.05);术后逆行射精患者共19例(11.52%),所有患者术后均无射精痛。结论:钬激光“ω”形预离断前列腺尖部治疗良性前列腺增生是安全有效的,术中采用保留膀胱颈的技术可以有效改善控尿功能,保护性功能。

低功率HoLEP与TUPKEP在老年原发性良性前列腺增生治疗中的近期疗效比较

目的观察低功率(60W)经尿道前列腺钬激光剜除术(HoLEP)与经尿道等离子前列腺剜除术(TUPKEP)在老年原发性良性前列腺增生治疗中的近期疗效。方法回顾性选取2016年3月至2022年12月在太原钢铁(集团)有限公司总医院106例老年原发性良性前列腺增生患者作为研究对象,按照治疗方法不同分为两组,每组各53例。观察组患者采用低功率HoLEP治疗,对照组患者采用TUPKEP治疗。比较两组手术相关指标(手术时间、出血量、膀胱冲洗时间、留置导尿管时间、住院时间),比较两组手术前后尿动力参数[最大尿流率(Qmax)、平均尿流率(Qave)、残余尿量(RUV)、有效膀胱容积(ECBC)]、生活质量(QOL)评分、国际勃起功能问卷-5(IIEF-5)评分、国际前列腺症状(IPSS)评分差异,并比较两组术后性功能情况和并发症发生情况。结果观察组的手术时间、膀胱冲洗时间、留置导尿管时间、住院时间分别为(77.06±8.56)min、(34.77±8.05)h、(48.05±6.96)h、(4.51±1.74)d,均短于对照组[(85.41±12.23)min、(47.45±9.63)h、(57.44±11.63)h、(6.55±2.41)d],出血量为(46.12±10.03)mL,少于对照组[(65.85±12.98)mL],差异均有统计学意义(P<0.05);两组的术中输液量和前列腺切除量比较,差异均无统计学意义(P>0.05)。观察组术后6个月Qmax、Qave、ECBC分别为(21.74±3.03)mL/s、(10.45±2.36)mL/s、(224.74±15.78)mL,均高于对照组[(17.86±2.86)mL/s、(8.47±2.11)mL/s、(197.85±12.66)mL],RUV为(13.36±5.44)mL,低于对照组[(25.86±8.05)mL],差异均有统计学意义(P<0.05)。观察组术后6个月IIEF-5评分为(21.96±3.01)分,高于对照组[(20.18±2.97)分],IPSS评分、QOL评分分别为(6.01±0.87)、(9.14±1.23)分,均低于对照组[(9.14±1.23)、(1.57±0.23)分],差异均有统计学意义(P<0.05)。观察组IIEF-5评分≤7分、逆行性射精发生率及并发症发生率与对照组比较,差异均无统计学意义(P>0.05)。结论低功率HoLEP治疗老年原发性良性前列腺增生的近期疗效优于TUPKEP,术后恢复较快,可改善尿动力参数,减轻症状,提高生活质量。

米拉贝隆在前列腺增生合并膀胱过度活动症行经尿道钬激光前列腺剜除术后早期应用的临床研究

目的:探讨米拉贝隆在前列腺增生(BPH)合并膀胱过度活动症(OAB)行经尿道钬激光前列腺剜除(HoLEP)术后早期应用的有效性和安全性。方法:选择2020年1月—2022年1月江苏大学附属武进医院收治的72例BPH合并OAB患者作为研究对象,随机分为两组,均在全身麻醉下行HoLEP,观察组36例接受米拉贝隆缓释片治疗,对照组36例不接受药物治疗,其中观察组3例患者因新冠疫情退出研究。比较两组并发症发生情况、前膀胱过度活动症评分表(OABSS)、生活质量(QOL)、国际前列腺症状评分(IPSS)、最大尿流率(Qmax)、残余尿量(PVR)及药物不良反应发生情况。结果:术后4周,两组QOL评分、排尿症状IPSS(V-IPSS)、总IPSS(T-IPSS)、最大尿流率(Qmax)、残余尿量(PVR)较术前均有改善,差异有统计学意义(P<0.05);对照组术后4周OABSS评分、储尿症状IPSS(S-IPSS)评分较术前下降,但差异无统计学意义(P>0.05);观察组术后4周OABSS评分、S-IPSS评分较术前及对照组术后下降,差异有统计学意义(P<0.05);观察组术后4周QOL评分、T-IPSS评分较对照组低,差异有统计学意义(P<0.05);但两组术后4周V-IPSS评分、Qmax、PVR比较,差异无统计学意义(P>0.05)。观察组口服米拉贝隆期间出现便秘2例(6.1%),对照组出现便秘1例(2.8%),两组比较差异无统计学意义(P>0.05)。结论:HoLEP术后早期应用米拉贝隆在不影响排尿功能的情况下,可进一步缓解BPH合并OAB患者下尿路症状。

直出式绿激光剜除结合汽化术治疗大体积良性前列腺增生的疗效及体会

目的探讨直出式绿激光剜除结合汽化术(FFGreenLEVP)治疗大体积良性前列腺增生的安全性及有效性。方法回顾性分析2019年1月至2022年12月南京医科大学第二附属医院收治的52例大体积良性前列腺增生患者的临床资料(试验组),前列腺体积80~120 mL,平均(88.92±8.37)mL,均采取FFGreenLEVP治疗。记录并分析手术时间、术中损失血红蛋白量、术中及术后并发症、术后住院时间、术后膀胱冲洗时间、术前及术后2个月国际前列腺症状评分(IPSS)、生活质量指数(QoL)及最大尿流率(Qmax)。将上述指标与2015年5月至2017年10月收治的31例采用经尿道前列腺切除术(TURP)治疗的大体积良性前列腺增生患者的临床资料(对照组)进行比较。结果所有接受FFGreenLEVP治疗的患者均顺利完成手术。手术时间(83.10±10.67)min。术中损失血红蛋白量(10.41±1.20)g。术后膀胱冲洗时间(1.55±0.63)d。术后有6例出现暂时性尿失禁,其中4例拔管后3 d内基本恢复尿控,2例拔管后1周恢复尿控。术后2个月IPSS及QoL评分均显著低于术前,Qmax显著高于术前,差异具有统计学意义(P<0.01)。术后1个月,1例出现轻度尿道外口狭窄,采用尿道扩张后治愈。有46例随访至今无明显复发。与对照组比较,试验组手术时间、术后冲洗时间更短(P<0.01);两组术后2个月QoL评分、IPSS、Qmax比较,差异无统计学意义(P>0.05)。结论FFGreenLEVP治疗大体积良性前列腺增生患者安全有效,可以同时发挥绿激光切割和汽化的优势。

钬激光前列腺剜除术与等离子电切术治疗良性前列腺增生的疗效及安全性比较

目的:对比钬激光前列腺剜除术(HoLEP)与等离子电切术(PKRP)治疗良性前列腺增生(BPH)的效果及安全性。方法:前瞻性选取2020年1月—2023年1月我院收治的138例BPH患者,按随机数字表法分为HoLEP组和PKRP组,每组69例,对比两组围术期相关指标、前列腺症状、生活质量、排尿功能、勃起功能、射精功能及术后并发症发生情况。结果:与PKRP组比较,HoLEP组手术时间较长,术中出血量较少,切除腺体重量较重,术后膀胱冲洗时间、导尿管留置时间及住院时间均较短(P<0.05)。术后3个月时,相较于PKRP组,HoLEP组的国际前列腺症状评分法(IPSS)、生活质量指数(QOL)得分较低(P<0.05),最大尿流率(Qmax)、平均尿流率(Qave)均较高(P<0.05),残余尿量(RUV)较少(P<0.05);HoLEP组的国际勃起功能指数(IIEF)-5评分、男性性健康问卷-射精功能障碍评分(MSHQ-EjD)量表中的射精功能评分均较高(P<0.05)。HoLEP组和PKRP组术后并发症发生率无统计学差异(P>0.05)。结论:相较于PKRP,HoLEP治疗BPH更具优势,手术创伤更小,术后前列腺症状及排尿功能改善更佳,且对患者勃起功能及射精功能的影响更小。

不同经尿道前列腺切除术治疗良性前列腺增生的疗效与安全性分析

目的探究不同经尿道前列腺切除术治疗良性前列腺增生的疗效与安全性分析。方法选取2021年1月至2023年5月本院收治的良性前列腺增生患者215例临床资料开展回顾性分析,根据手术方式分为经尿道前列腺等离子电切术治疗的等离子电切术组(n=81)、经尿道前列腺激光切除术治疗的激光切除术组(n=92)、经尿道前列腺绿激光剜除术治疗的绿激光剜除术组(n=42),比较三组围手术期指标(手术时间、术中出血量、膀胱冲洗时间、留置尿管时间、术后血红蛋白浓度、住院时间)、尿动力学指标(RUV、IPSS评分、Qmax、QOL评分)、术后并发症发生情况的差异。结果绿激光剜除术组、激光切除术组总有效率高于等离子电切术组(P<0.05)。3组住院时间比较差异无统计学意义(P>0.05),但绿激光剜除术组手术时间>激光切除术组>等离子电切术组(P<0.05),绿激光剜除术组、激光切除术组术中出血量、膀胱冲洗时间、留置尿管时间<等离子电切术组,且术后血红蛋白浓度>等离子电切术组(P<0.05)。重复测量方差分析结果显示,3组术后1个月、术后3个月RUV、IPSS评分、QOL评分与术前相比均降低,而Qmax与术前相比均升高(P<0.05),且激光切除术组与绿激光剜除术组术后1个月、术后3个月RUV、IPSS评分、QOL评分均低于等离子电切术组,Qmax均高于等离子电切术组(P<0.05),但激光切除术组与绿激光剜除术组术后1个月、术后3个月RUV、IPSS评分、Qmax、QOL评分比较差异无统计学意义(P>0.05)。绿激光剜除术组术后并发症总发生率<激光切除术组<等离子电切术组(7.14%vs.21.74%vs.35.80%,P<0.05)。结论3种手术方式治疗良性前列腺增生均具有较好疗效,但经尿道前列腺激光切除术与绿激光剜除术疗效与安全性均优于经尿道前列腺等离子电切术,可促进患者早期康复,且经尿道前列腺绿激光剜除术治疗安全性最好。

不同功率HoLEP联合钬激光碎石术在治疗良性前列腺增生合并膀胱结石的疗效及安全性分析

目的:研究不同功率钬激光前列腺剜除术(HoLEP)联合钬激光碎石术(HLC)在治疗良性前列腺增生(BPH)合并膀胱结石的疗效及安全性分析。方法:收集2019年1月至2024年1月丹阳市人民医院收治的110例BPH合并膀胱结石患者的临床资料,根据手术方式,将接受高功率HoLEP联合HLC的患者纳入HP组(n=62),接受低功率HoLEP联合HLC的患者纳入LP组(n=48)。比较两组围术期指标、排尿功能、应激指标、术后并发症。结果:HP组手术时间(68.49±15.36)min、剜除组织质量(41.42±10.59)g、膀胱冲洗时间(1.86±0.66)d、术后尿管留置时间(2.34±0.85)d与LP组[(70.15±15.71)min、(42.81±9.93)g、(1.81±0.72)d、(2.58±0.92)d]比较差异无统计学意义(P>0.05);HP组腺体剜除时间(35.80±7.21)min、住院时间(3.62±0.64)d短于LP组[(41.64±7.83)min、(3.86±0.50)d],剜除效率(1.15±0.25)g/min、血红蛋白下降幅度(8.05±1.58)g/L高于LP组[(1.02±0.18)g/min、(7.36±1.72)g/L],差异有统计学意义(P<0.05);术后3个月,HP组Qmax、PVR、PSA治疗前后差值与LP组比较差异无统计学意义(P>0.05);术后24h,HP组SP、PGE2、NE治疗前后差值与LP组比较差异无统计学意义(P>0.05);HP组术后并发症(12.88%)与LP组(10.40%)比较,差异无统计学意义(P>0.05)。结论:高功率、低功率HoLEP联合HLC对BPH合并膀胱结石的疗效相当,高功率HoLEP剜除效率更高,腺体剜除时间、住院时间更短,低功率HoLEP的止血效果更好。

小蓟饮子加减防治经尿道前列腺钬激光剜除术后血尿的临床效果研究

目的观察小蓟饮子加减防治经尿道前列腺钬激光剜除术(HoLEP)后血尿的临床疗效。方法选取60例前列腺增生患者,根据治疗方案分为观察组和对照组,各30例。所有患者均行HoLEP,对照组术后给予常规治疗加氨甲苯酸注射治疗,观察组术后在对照组基础上给予小蓟饮子加减治疗。比较两组术后的相关指标(膀胱冲洗时间、留置导尿管时间、术后住院时间);术后6 h、术后第1~4天导尿管引流液颜色;术后1个月的并发症(血尿、尿道狭窄、尿路感染、尿失禁)发生率。结果观察组的膀胱冲洗时间、导尿管留置时间、术后住院时间分别为(40.50±3.48)h、(5.13±0.78)d、(5.20±0.96)d,均比对照组的(52.70±3.92)h、(6.87±0.73)d、(7.03±0.72)d短(P<0.05)。术后6 h,两组引流液颜色相似(P>0.05);术后第1~4天,观察组导尿管引流液颜色均优于对照组(P<0.05)。观察组术后并发症发生率13.33%低于对照组的40.00%,差异有统计学意义(P<0.05)。结论小蓟饮子能够明显改善前列腺增生患者HoLEP术后相关指标、出血程度和血尿持续时间,降低并发症发生率,提高患者术后生活质量。

经尿道前列腺钬激光剜除术治疗复发前列腺增生患者的临床分析

目的:研究经尿道前列腺钬激光剜除术治疗复发前列腺增生患者的临床效果。方法:收集承德市中心医院泌尿外科于2020年9月至2023年9月期间所收治的60例经尿道前列腺电切术(TURP)后再次出现中重度下尿路梗阻症状的患者为研究对象,并按随机数字表法,将其平分为两组:对照组与观察组,每组患者各30例。对照组行前列腺电切术,观察组行经尿道前列腺钬激光剜除术,对比两组临床疗效。结果:治疗前,两组患者前列腺功能、康复评分均无显著差异(P>0.05);治疗后,两组患者均有显著改善情况(P<0.05),且观察组显著优于对照组,差异有统计学意义(P<0.05)。观察组术后并发症发生率低于对照组(P<0.05);观察组手术时间、住院时间、出血量、膀胱冲洗时间等临床指标,均优于对照组(P<0.05)。结论:在复发前列腺增生的手术治疗中,经尿道前列腺钬激光剜除术不仅提升了手术治疗效果与安全性,还能降低术后并发症的发生率,值得临床推广。